356 related articles for article (PubMed ID: 17512720)
21. Diagnostic accuracy of serum-carcinoembryonic antigen in recurrent colorectal cancer: a receiver operating characteristic curve analysis.
Körner H; Söreide K; Stokkeland PJ; Söreide JA
Ann Surg Oncol; 2007 Feb; 14(2):417-23. PubMed ID: 17103264
[TBL] [Abstract][Full Text] [Related]
22. Stool test for colorectal cancer screening: what is going on?
Bonanno E; Rulli F; Galatà G; Pucci S; Sesti F; Farinon AM; Spagnoli LG
Surg Oncol; 2007 Dec; 16 Suppl 1():S43-5. PubMed ID: 18055195
[TBL] [Abstract][Full Text] [Related]
23. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.
Kumar Y; Tapuria N; Kirmani N; Davidson BR
Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):265-76. PubMed ID: 17301655
[TBL] [Abstract][Full Text] [Related]
24. Comparative analysis of prognostic significance of molecular markers of apoptosis with clinical stage and tumor differentiation in patients with colorectal cancer: a single institute experience.
Ivanov K; Kolev N; Tonev A; Nikolova G; Krasnaliev I; Softova E; Tonchev A
Hepatogastroenterology; 2009; 56(89):94-8. PubMed ID: 19453036
[TBL] [Abstract][Full Text] [Related]
25. [New histologic prognostic factors in colorectal cancer].
Piard F; Martin L; Chapusot C; Ponnelle T; Monges G
Gastroenterol Clin Biol; 2002 May; 26(5 Suppl):B62-73. PubMed ID: 12068272
[No Abstract] [Full Text] [Related]
26. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases.
Kumar Y; Pinedo IR; Tapuria N; Zabron A; Davidson BR
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469
[TBL] [Abstract][Full Text] [Related]
27. Minimally invasive biomarkers for detection and staging of colorectal cancer.
Booth RA
Cancer Lett; 2007 Apr; 249(1):87-96. PubMed ID: 17275174
[TBL] [Abstract][Full Text] [Related]
28. Identification of Cystatin SN as a novel tumor marker for colorectal cancer.
Yoneda K; Iida H; Endo H; Hosono K; Akiyama T; Takahashi H; Inamori M; Abe Y; Yoneda M; Fujita K; Kato S; Nozaki Y; Ichikawa Y; Uozaki H; Fukayama M; Shimamura T; Kodama T; Aburatani H; Miyazawa C; Ishii K; Hosomi N; Sagara M; Takahashi M; Ike H; Saito H; Kusakabe A; Nakajima A
Int J Oncol; 2009 Jul; 35(1):33-40. PubMed ID: 19513549
[TBL] [Abstract][Full Text] [Related]
29. Fecal cyclooxygenase 2 plus matrix metalloproteinase 7 mRNA assays as a marker for colorectal cancer screening.
Takai T; Kanaoka S; Yoshida K; Hamaya Y; Ikuma M; Miura N; Sugimura H; Kajimura M; Hishida A
Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1888-93. PubMed ID: 19505922
[TBL] [Abstract][Full Text] [Related]
30. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines.
Duffy MJ; van Dalen A; Haglund C; Hansson L; Klapdor R; Lamerz R; Nilsson O; Sturgeon C; Topolcan O
Eur J Cancer; 2003 Apr; 39(6):718-27. PubMed ID: 12651195
[TBL] [Abstract][Full Text] [Related]
31. [Fecal oncomarkers in the diagnostics of colorectal cancer].
Mikhaĭlova EI; Pimanov SI; Voropaev EV
Klin Med (Mosk); 2007; 85(12):62-7. PubMed ID: 18318171
[TBL] [Abstract][Full Text] [Related]
32. Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer.
Malesci A; Laghi L; Bianchi P; Delconte G; Randolph A; Torri V; Carnaghi C; Doci R; Rosati R; Montorsi M; Roncalli M; Gennari L; Santoro A
Clin Cancer Res; 2007 Jul; 13(13):3831-9. PubMed ID: 17606714
[TBL] [Abstract][Full Text] [Related]
33. P53 mutations in colorectal cancer from northern Iran: Relationships with site of tumor origin, microsatellite instability and K-ras mutations.
Mahdavinia M; Bishehsari F; Verginelli F; Cumashi A; Lattanzio R; Sotoudeh M; Ansari R; Semeraro D; Hormazdi M; Fakheri H; Rakhshani N; De Lellis L; Curia MC; Cama A; Piantelli M; Malekzadeh R; Iacobelli S; Mariani-Costantini R
J Cell Physiol; 2008 Aug; 216(2):543-50. PubMed ID: 18330889
[TBL] [Abstract][Full Text] [Related]
34. Liver metastasis of colorectal cancer by protein-tyrosine phosphatase type 4A, 3 (PRL-3) is mediated through lymph node metastasis and elevated serum tumor markers such as CEA and CA19-9.
Hatate K; Yamashita K; Hirai K; Kumamoto H; Sato T; Ozawa H; Nakamura T; Onozato W; Kokuba Y; Ihara A; Watanabe M
Oncol Rep; 2008 Oct; 20(4):737-43. PubMed ID: 18813812
[TBL] [Abstract][Full Text] [Related]
35. Free circulating DNA as possible tumour marker in colorectal cancer.
Boni L; Cassinotti E; Canziani M; Dionigi G; Rovera F; Dionigi R
Surg Oncol; 2007 Dec; 16 Suppl 1():S29-31. PubMed ID: 18024018
[TBL] [Abstract][Full Text] [Related]
36. Factors predicting survival in surgical palliative resection of stage IV colorectal cancer.
Scabini S; Rimini E; Romairone E; Scordamaglia R; Pertile D; Ferrando V
Minerva Chir; 2009 Jun; 64(3):303-6. PubMed ID: 19536056
[TBL] [Abstract][Full Text] [Related]
37. Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer.
Koike Y; Miki C; Okugawa Y; Yokoe T; Toiyama Y; Tanaka K; Inoue Y; Kusunoki M
J Surg Oncol; 2008 Dec; 98(7):540-4. PubMed ID: 18937231
[TBL] [Abstract][Full Text] [Related]
38. Detection of survivin-expressing circulating cancer cells (CCCs) in peripheral blood of patients with gastric and colorectal cancer reveals high risks of relapse.
Yie SM; Lou B; Ye SR; Cao M; He X; Li P; Hu K; Rao L; Wu SM; Xiao HB; Gao E
Ann Surg Oncol; 2008 Nov; 15(11):3073-82. PubMed ID: 18670822
[TBL] [Abstract][Full Text] [Related]
39. The use of serologic tumor markers in gastrointestinal malignancies.
Posner MR; Mayer RJ
Hematol Oncol Clin North Am; 1994 Jun; 8(3):533-53. PubMed ID: 8707771
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
